Scandion Oncology (SCOL) | Spotlight

Home

Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen.

Quotes for Scandion Oncology

Right Now

+/-: -0.14
%: -3,03%
Latest: 4.48
High: 4.7
Low: 4.46
Volume: 7 576
Turnover (SEK): 34 678
Value (MSEK): 53,3

Board

CEO

Nils Brünner

Chairman Of The Board

Jørgen Bardenfleth

Board

Carl Borrebäck
Peter Høngaard
Thomas Feldthus

Articles of association

News

2019-06-17 16:08:57 Scandion Oncology A/S publishes prospectus in connection with rights issue
2019-06-13 14:37:07 Spotlight: Market Notice 159/19 - Update - Information regarding the rights issue from Scandion Oncology A/S
2019-06-11 15:01:09 Spotlight: Market Notice 152/19 - Information regarding the rights issue from Scandion Oncology A/S
2019-06-11 11:42:08 Communique from the Extraordinary General Meeting in Scandion Oncology A/S
2019-06-06 11:24:07 Scandion Oncology appoints Chairman and Vice-Chairman of its Board of Directors

Show More

News agencies

2019-06-13 07:01:00 Finwire: Scandion Oncology handlas idag exklusive uniträtt i nyemission
2019-06-03 12:21:47 Finwire: Storaktionærer indgår lock-up-bestemmelse i Scandion Oncology efter nyemission
2019-05-27 10:28:55 Finwire: Scandion Oncology dykker 22 procent efter melding om ny aktieemission
2019-05-27 10:18:57 Finwire: Scandion Oncology vil hente 41 mio. svenske kroner gennem aktieemission
2019-05-27 09:59:30 Finwire: Scandion Oncology genomför nyemission av units på 41,7 miljoner kronor

Show More

Analysis

2018-10-09 SvD Börsplus: Svår att motstå?

Videos

Key Numbers

*Compiled data from Inquiry Financial

Upcoming reports

2019-08-22 Delårsrapport 2019-Q2
2019-11-19 Delårsrapport 2019-Q3

Annual reports, prospectus etc.